LivaNova stock moved higher in after-hours trading, gaining 1.3% to $86.42 after the medical technology company posted second-quarter 2026 results that topped analyst forecasts on both the top and bottom lines.
Quarterly results
Adjusted earnings per share came in at $1.26, outperforming the analyst consensus of $1.09 by $0.17. Quarterly revenue reached $390.6 million, above the $380.57 million estimate and representing a 10.8% increase versus the same period a year earlier.
Guidance and growth drivers
Management raised its full-year 2026 adjusted diluted EPS guidance to a range of $4.30 to $4.40. The midpoint of that range - $4.35 - exceeds the analyst consensus of $4.25. This marks the second straight quarter in which LivaNova has boosted its annual profit outlook.
The company attributed the upgraded guidance to continued strength across its cardiopulmonary segment and to the growing commercial opportunity associated with the aura6000 system, the company’s recently FDA-approved hypoglossal nerve stimulation device for obstructive sleep apnea. The aura6000 is cited in the results as an additional growth vector alongside LivaNova’s established cardiopulmonary and neuromodulation businesses.
Analyst reaction
KeyBanc analyst Brett Fishbin kept an Overweight rating on LivaNova shares and raised his price target to $92 from $83. The analyst’s move reflects a more favorable assessment of the company’s earnings power following the quarter.
Market context and stock momentum
The wider market provided a broadly neutral backdrop on the day. The S&P 500 rose 0.4% and the Dow Jones Industrial Average added 0.3%, while the Nasdaq was essentially flat. That relative calm suggests LivaNova’s after-hours advance was driven primarily by company-specific fundamentals rather than a broad market rally.
During the regular session the shares hit a new 52-week high of $85.76, building on the stock’s substantial recovery from a 52-week low of $45.64.
Investor takeaway
Taken together, the decisive earnings beat, the upward revision to full-year guidance, and renewed analyst confidence provided clear catalysts for investor buying after hours. The addition of the aura6000 device to LivaNova’s product mix was highlighted by management as a fresh commercial opportunity that complements the company’s existing franchises.